Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Copyright West LLC. Minimum 15 minutes delayed.
- Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD
- Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer
Sep 5, 2019 at 10:15 AM EDT
Jun 22, 2019
Jun 5, 2019